Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; magnesium carbonate hydrate; calcium sulfate dihydrate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; xanthan gum; iron oxide yellow; purified talc; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - quinapril hydrochloride, quantity: 21.7 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; magnesium oxide; crospovidone; titanium dioxide; hypromellose; iron oxide yellow; polysorbate 80; iron oxide black; macrogol 400 - hypertension: quinapril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril in severe hypertension or renovascular hypertension. congestive heart failure: quinapril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - quinapril hydrochloride, quantity: 9.972 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; magnesium oxide; purified water; titanium dioxide; hypromellose; iron oxide yellow; polysorbate 80; iron oxide black; macrogol 400 - hypertension: quinapril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril in severe hypertension or renovascular hypertension. congestive heart failure: quinapril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - quinapril hydrochloride, quantity: 5.42 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; magnesium oxide; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; polysorbate 80; iron oxide black; macrogol 400 - hypertension: quinapril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril in severe hypertension or renovascular hypertension. congestive heart failure: quinapril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; iron oxide red; iron oxide yellow; sodium bicarbonate; lactose monohydrate; magnesium stearate - auspril tablets are indicated in the treatment of: hypertension: all grades of essential hypertension renovascular hypertension. congestive heart failure: all degrees of symptomatic heart failure. in such patients, it is recommended that auspril be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; pregelatinised maize starch; sodium bicarbonate; iron oxide red; lactose monohydrate; magnesium stearate - auspril tablets are indicated in the treatment of: hypertension: all grades of essential hypertension renovascular hypertension. congestive heart failure: all degrees of symptomatic heart failure. in such patients, it is recommended that auspril be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cilazapril monohydrate 1.043mg equivalent to cilazapril 1 mg;   - tablet - 1 mg - active: cilazapril monohydrate 1.043mg equivalent to cilazapril 1 mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f92084 purified water - cilazapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. cilazapril is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cilazapril monohydrate 2.608mg equivalent to cilazapril 2.5 mg;   - tablet - 2.5 mg - active: cilazapril monohydrate 2.608mg equivalent to cilazapril 2.5 mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f14364 purified water - cilazapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. cilazapril is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cilazapril monohydrate 5.215mg equivalent to cilazapril 5 mg;   - tablet - 5 mg - active: cilazapril monohydrate 5.215mg equivalent to cilazapril 5 mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry brown 85f16874 purified water - cilazapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. cilazapril is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; lactose monohydrate; pregelatinised maize starch; maize starch; magnesium stearate - hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence of severity of obvious symptoms of heart failure.